Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Novo Nordisk 12.087, Viking Therapeutics 0.
Novo Nordisk vs Viking Therapeutics Net Worth and Market Cap
Novo Nordisk (NVO) and Viking Therapeutics (VKTX) are peers in GLP-1. Novo Nordisk reported revenue of $12.1B as of Q2 2026, compared with $0 for Viking Therapeutics. Novo Nordisk leads on revenue.
Key differences
- Novo Nordisk's KPIs on Sterling include Next-Generation Obesity: CagriSema + Amycretin Readouts and 2030 Ambitions (Capital Markets Day, 21 Sep 2026).
- Viking Therapeutics's KPIs on Sterling include Cash + Short-Term Investments (Quarterly) and Viking Oral VK2735 Phase 3 Timing.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Novo Nordisk, Viking Therapeutics.| Metric | Novo Nordisk | Viking Therapeutics |
|---|---|---|
| Market Cap | - | - |
| Revenue | $12.09B | $0 |
| Cost of Revenue | $2.63B | $0 |
| Gross Profit | $9.45B | $0 |
| Operating Income | $4.17B | $-164.00M |
| Net Income | $3.23B | $-158.00M |
| R&D Expense | $2.74B | $150.00M |
| Earnings Per Share | $0.73 | -$1.37 |
| Gross Margin | 78.2% | - |
| Operating Margin | 34.5% | - |
| Net Profit Margin | 26.7% | - |
| Free Cash Flow | $6.53B | $-114.00M |
| Cumulative Free Cash Flow | $107.39B | $-747.00M |
| Operating Cash Flow | $8.50B | $-114.00M |
| Cash & Equivalents | $6.85B | $118.00M |